• Something wrong with this record ?

Utility of Immunohistochemistry With Antibodies to SS18-SSX Chimeric Proteins and C-Terminus of SSX Protein for Synovial Sarcoma Differential Diagnosis

J. Lasota, M. Chłopek, M. Kaczorowski, K. Natálie, J. Ryś, J. Kopczyński, O. Sulaieva, M. Michal, A. Kruczak, A. Harazin-Lechowska, M. Szczepaniak, O. Koshyk, A. Hałoń, P. Czapiewski, Z. Abdullaev, A. Kowalik, KD. Aldape, M. Michal, M. Miettinen

. 2024 ; 48 (1) : 97-105. [pub] 20231027

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24000124

Synovial sarcoma is a relatively common soft tissue tumor characterized by highly specific t(X;18)(p11;q11) translocation resulting in the fusion of SS18 with members of SSX gene family. Typically, detection of SS18 locus rearrangement by fluorescence in situ hybridization or SS18 :: SSX fusion transcripts confirms the diagnosis. More recently, immunohistochemistry (IHC) for SS18-SSX chimeric protein (E9X9V) and C-terminus of SSX (E5A2C) showed high specificity and sensitivity for synovial sarcoma. This study screened a cohort of >1000 soft tissue and melanocytic tumors using IHC and E9X9V and E5A2C antibodies. Three percent (6/212) of synovial sarcomas were either negative for SS18-SSX or had scattered positive tumor cells (n=1). In these cases, targeted RNA next-generation sequencing detected variants of SS18 :: SSX chimeric transcripts. DNA methylation profiles of 2 such tumors matched with synovial sarcoma. A few nonsynovial sarcoma tumors (n=6) revealed either focal SS18-SSX positivity (n=1) or scattered positive tumor cells. However, targeted RNA next-generation sequencing failed to detect SS18 :: SSX transcripts in these cases. The nature of this immunopositivity remains elusive and may require single cell sequencing studies. All synovial sarcomas showed positive SSX IHC. However, a mosaic staining pattern or focal loss of expression was noticed in a few cases. Strong and diffuse SSX immunoreactivity was also seen in epithelioid sclerosing osteosarcoma harboring EWSR1 :: SSX1 fusion, while several sarcomas and melanocytic tumors including cellular blue nevus (5/7, 71%) revealed focal to diffuse, mostly weak to intermediate SSX staining. The SS18-SSX and SSX IHC is a useful tool for synovial sarcoma differential diagnosis, but unusual immunophenotype should trigger molecular genetic testing.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000124
003      
CZ-PrNML
005      
20240213092956.0
007      
ta
008      
240109s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/PAS.0000000000002144 $2 doi
035    __
$a (PubMed)37899499
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Lasota, Jerzy $u Laboratory of Pathology, National Cancer Institute, Bethesda, MD
245    10
$a Utility of Immunohistochemistry With Antibodies to SS18-SSX Chimeric Proteins and C-Terminus of SSX Protein for Synovial Sarcoma Differential Diagnosis / $c J. Lasota, M. Chłopek, M. Kaczorowski, K. Natálie, J. Ryś, J. Kopczyński, O. Sulaieva, M. Michal, A. Kruczak, A. Harazin-Lechowska, M. Szczepaniak, O. Koshyk, A. Hałoń, P. Czapiewski, Z. Abdullaev, A. Kowalik, KD. Aldape, M. Michal, M. Miettinen
520    9_
$a Synovial sarcoma is a relatively common soft tissue tumor characterized by highly specific t(X;18)(p11;q11) translocation resulting in the fusion of SS18 with members of SSX gene family. Typically, detection of SS18 locus rearrangement by fluorescence in situ hybridization or SS18 :: SSX fusion transcripts confirms the diagnosis. More recently, immunohistochemistry (IHC) for SS18-SSX chimeric protein (E9X9V) and C-terminus of SSX (E5A2C) showed high specificity and sensitivity for synovial sarcoma. This study screened a cohort of >1000 soft tissue and melanocytic tumors using IHC and E9X9V and E5A2C antibodies. Three percent (6/212) of synovial sarcomas were either negative for SS18-SSX or had scattered positive tumor cells (n=1). In these cases, targeted RNA next-generation sequencing detected variants of SS18 :: SSX chimeric transcripts. DNA methylation profiles of 2 such tumors matched with synovial sarcoma. A few nonsynovial sarcoma tumors (n=6) revealed either focal SS18-SSX positivity (n=1) or scattered positive tumor cells. However, targeted RNA next-generation sequencing failed to detect SS18 :: SSX transcripts in these cases. The nature of this immunopositivity remains elusive and may require single cell sequencing studies. All synovial sarcomas showed positive SSX IHC. However, a mosaic staining pattern or focal loss of expression was noticed in a few cases. Strong and diffuse SSX immunoreactivity was also seen in epithelioid sclerosing osteosarcoma harboring EWSR1 :: SSX1 fusion, while several sarcomas and melanocytic tumors including cellular blue nevus (5/7, 71%) revealed focal to diffuse, mostly weak to intermediate SSX staining. The SS18-SSX and SSX IHC is a useful tool for synovial sarcoma differential diagnosis, but unusual immunophenotype should trigger molecular genetic testing.
650    _2
$a lidé $7 D006801
650    12
$a synoviom $x diagnóza $x genetika $x patologie $7 D013584
650    _2
$a imunohistochemie $7 D007150
650    _2
$a diferenciální diagnóza $7 D003937
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a fúzní onkogenní proteiny $x genetika $x metabolismus $7 D015514
650    12
$a nádory měkkých tkání $x diagnóza $x genetika $7 D012983
650    _2
$a RNA $7 D012313
650    _2
$a rekombinantní fúzní proteiny $x genetika $7 D011993
655    _2
$a časopisecké články $7 D016428
700    1_
$a Chłopek, Małgorzata $u Laboratory of Pathology, National Cancer Institute, Bethesda, MD $u Department of Molecular Diagnostics, Holycross Cancer Center
700    1_
$a Kaczorowski, Maciej $u Laboratory of Pathology, National Cancer Institute, Bethesda, MD $u Department of Clinical and Experimental Pathology, Wrocław Medical University, Wrocław
700    1_
$a Natálie, Klubíčková $u Sikl's Institute of Pathology, Faculty of Medicine and Teaching Hospital in Plzen, Charles University, Plzen, Czech Republic
700    1_
$a Ryś, Janusz $u Department of Tumor Pathology, Maria Skłodowska-Curie National Research Institute of Oncology, Cracow Branch, Krakow, Poland
700    1_
$a Kopczyński, Janusz $u Department of Pathology, Holycross Cancer Center
700    1_
$a Sulaieva, Oksana $u Department of Clinical Pathology, Medical Laboratory Care and Safe Diagnostics (CSD), Kyiv, Ukraine
700    1_
$a Michal, Michael $u Sikl's Institute of Pathology, Faculty of Medicine and Teaching Hospital in Plzen, Charles University, Plzen, Czech Republic
700    1_
$a Kruczak, Anna $u Department of Tumor Pathology, Maria Skłodowska-Curie National Research Institute of Oncology, Cracow Branch, Krakow, Poland
700    1_
$a Harazin-Lechowska, Agnieszka $u Department of Tumor Pathology, Maria Skłodowska-Curie National Research Institute of Oncology, Cracow Branch, Krakow, Poland
700    1_
$a Szczepaniak, Magdalena $u Department of Molecular Diagnostics, Holycross Cancer Center
700    1_
$a Koshyk, Olena $u Medical Laboratory, CSD, Kyiv, Ukraine
700    1_
$a Hałoń, Agnieszka $u Department of Clinical and Experimental Pathology, Wrocław Medical University, Wrocław
700    1_
$a Czapiewski, Piotr $u Department of Pathology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau $u Institute of Pathology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
700    1_
$a Abdullaev, Zied $u Laboratory of Pathology, National Cancer Institute, Bethesda, MD
700    1_
$a Kowalik, Artur $u Department of Molecular Diagnostics, Holycross Cancer Center $u Division of Medical Biology, Institute of Biology Jan Kochanowski University, Kielce
700    1_
$a Aldape, Kenneth D $u Laboratory of Pathology, National Cancer Institute, Bethesda, MD
700    1_
$a Michal, Michal $u Sikl's Institute of Pathology, Faculty of Medicine and Teaching Hospital in Plzen, Charles University, Plzen, Czech Republic
700    1_
$a Miettinen, Markku $u Laboratory of Pathology, National Cancer Institute, Bethesda, MD
773    0_
$w MED00000304 $t The American journal of surgical pathology $x 1532-0979 $g Roč. 48, č. 1 (2024), s. 97-105
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37899499 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213092953 $b ABA008
999    __
$a ok $b bmc $g 2049047 $s 1209818
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 48 $c 1 $d 97-105 $e 20231027 $i 1532-0979 $m The American journal of surgical pathology $n Am J Surg Pathol $x MED00000304
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options